The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Diabetes mellitus in patients with cirrhosis: clinical implications and management
Abstract
Disorders of glucose metabolism, namely glucose intolerance and diabetes, are frequent in patients with chronic liver diseases. In patients with cirrhosis, diabetes can be either a classical type 2 diabetes mellitus or the so‐called hepatogenous diabetes, i.e. a consequence of liver insufficiency and portal hypertension. This review article provides an overview of the possible pathophysiological mechanisms explaining diabetes in patients with cirrhosis. Cirrhosis is associated with portosystemic shunts as well as reduced hepatic mass, which can both impair insulin clearance by the liver, contributing to peripheral insulin resistance through insulin receptors down‐regulation. Moreover, cirrhosis is associated with increased levels of advanced‐glycation‐end products and hypoxia‐inducible‐factors, which may play a role in the development of diabetes. This review also focuses on the clinical implications of diabetes in patients with cirrhosis. First, diabetes is an independent factor for poor prognosis in patients with cirrhosis. Specifically, diabetes is associated with the occurrence of major complications of cirrhosis, including ascites and renal dysfunction, hepatic encephalopathy and bacterial infections. Diabetes is also associated with an increased risk of hepatocellular carcinoma in patients with chronic liver diseases. Last, the management of patients with concurrent diabetes and liver disease is also addressed. Recent findings suggest a beneficial impact of metformin in patients with chronic liver diseases. Insulin is often required in patients with advanced cirrhosis. However, the favourable impact of controlling diabetes in patients with cirrhosis has not been demonstrated yet.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Type 2 diabetes as an inflammatory disease
Donath, M. Y., & Shoelson, S. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2925 · Cited by 3,737
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842 · cited 1×
“In a chronically injured liver, hepatic stellate cells promote liver fibrosis through excessive extra-cellular matrix production and reduced extra-cellular matrix degradation (10).”
BackgroundDiabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726 · cited 5×
“Keywords ascites – hepatic encephalopathy – hepatocellular carcinoma – hepatogenous diabetes – metformin Abbreviations AGEs, advanced glycation-end products; CTGF, connective tissue growth factor; DPP-4, Dipeptyl peptidase-4; GLP-1, glucagon-like peptide-1; HbA1c, glycated haemoglobin; HCC, hepatocellular carcinoma; H…”
BackgroundInfluentialHarris, M. I., Flegal, K. M., Cowie, C. C., Eberhardt, M. S., Goldstein, D. E., Little, R. R., Wiedmeyer, H.-M., & Byrd-Holt, D. D. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.518 · Cited by 2,703
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
Hepatic inflammation and fibrosis: Functional links and key pathways
Seki, E., & Schwabe, R. F. (2015) · Hepatology · doi:10.1002/hep.27332 · Cited by 972
Fernández, J., Navasa, M., Gómez, J., Colmenero, J., Vila, J., Arroyo, V., & Rodés, J. (2002) · Hepatology · doi:10.1053/jhep.2002.30082 · Cited by 954
Insulin Resistance and Hyperinsulinemia
Shanik, M. H., Xu, Y., Škrha, J., Dankner, R., Zick, Y., & Roth, J. (2008) · Diabetes Care · doi:10.2337/dc08-s264 · Cited by 791
Disorders of gastrointestinal motility associated with diabetes mellitus
FELDMAN, M., & SCHILLER, L. R. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-3-378 · Cited by 653
Cited by
Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors
Huang, D. Q., Mathurin, P., Cortez-Pinto, H., & Loomba, R. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00688-6 · Cited by 553
Evidence-based clinical practice guidelines for Liver Cirrhosis 2020
Yoshiji, H., Nagoshi, S., Akahane, T., Asaoka, Y., Ueno, Y., Ogawa, K., Kawaguchi, T., Kurosaki, M., Sakaida, I., Shimizu, M., et al. (2021) · Journal of Gastroenterology · doi:10.1007/s00535-021-01788-x · Cited by 422
Nutrition in Patients with Type 2 Diabetes: Present Knowledge and Remaining Challenges
Petroni, M. L., Brodosi, L., Marchignoli, F., Sasdelli, A. S., Caraceni, P., Marchesini, G., & Ravaioli, F. (2021) · Nutrients · doi:10.3390/nu13082748 · Cited by 116
Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients
Ma, S., Zheng, Y., Xiao, Y., Zhou, P., & Tan, H. (2017) · Medicine · doi:10.1097/md.0000000000006888 · Cited by 89
Elsaid, M. I., Li, N., Firkins, S. A., Rustgi, V. K., Paskett, E. D., Acharya, C., Reddy, K. R., Chiang, C. W., & Mumtaz, K. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17925 · Cited by 77
“12,39 Diabetes, which is disproportionally prevalent in MASLD, is also an established risk factor for major complications of cirrhosis 9 and liver-related mortality.”
Background
Metadata
- Authors
- Elkrief, L., Rautou, P., Sarin, S., Valla, D., Paradis, V., & Moreau, R.
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2016-04-04
- Volume
- 36
- Issue
- 7
- Pages
- 936-948
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W2296384476
- Cited by
- 220
- References
- 22
- FWCI
- 9.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diabetes mellitus in patients with cirrhosis: clinical implications and management. https://app.cochat.ai/papers/10.1111/liv.13115
- The paper
- Elkrief, L., Rautou, P., Sarin, S., Valla, D., Paradis, V., & Moreau, R. (2016). Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver International. https://doi.org/10.1111/liv.13115
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.